COVID-19 testing

EQS-News: SYNLAB delivers robust performance in FY 2023

Retrieved on: 
Wednesday, April 10, 2024
AOP, EV, COVID, Growth, Synnovis, Supervisory board, North, Environment, COVID-19 testing, FY, EPS, Cinven, COVID-19, Hospital, Sale, Acquisition, GBP, Ontario Teachers' Pension Plan, Novo Nordisk Foundation, Term loan, FX, Movement, State, Pharmaceutical industry

Synnovis, the South East London hospital outsourcing contract grew 12.2% in 2023 and contributed 0.6pts to the overall 2023 underlying organic growth.

Key Points: 
  • Synnovis, the South East London hospital outsourcing contract grew 12.2% in 2023 and contributed 0.6pts to the overall 2023 underlying organic growth.
  • FY 2023 adjusted EBITDA (AEBITDA) was €438 million (FY 2022: €753 million) while adjusted operating profit (AOP) was €194 million (FY 2022: €508 million) with margins of 16.6% (FY 2022: 23.2%) and 7.4% (FY 2022: 15.6%), respectively.
  • In FY 2023, adjusted net profit (Group share) was €44 million (FY 2022: €342 million), mainly due to lower COVID-19 testing volumes and higher net finance costs.
  • FY 2023 unlevered free cash flow (uFCF) was €74 million (FY 2022: €312 million).

Q&M Dental Group recorded growth in both Revenue and Net Profit after tax attributable to parent of S$182.7 million and S$11.5 million respectively for FY2023

Retrieved on: 
Friday, March 1, 2024
Philosophy, COVID-19, Morale, SARS-CoV-2, Dentist, Culture, Into, Growth, Dentistry, Nursing, COVID-19 testing, Patient, Tax, Knowledge, Artificial intelligence, Research, Depreciation

Comparing FY2023 with FY2022, share of loss in Aoxin Q & M, decreased by S$0.5 million for the same reason give above.

Key Points: 
  • Comparing FY2023 with FY2022, share of loss in Aoxin Q & M, decreased by S$0.5 million for the same reason give above.
  • This is mainly attributable to operating cash flow before changes in working capital offset by increase on working capital.
  • As at 31 December 2023, Q & M has cash and cash equivalents of S$34.0 million and bank borrowings plus finance leases amounting to S$80.3 million.
  • Net Aset Value attributable to owners of parent is S$99.1 million as at 31 December 2023 compared to S$96.5 million a year ago, an increase of 3%.

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Tuesday, February 27, 2024
International, Pfizer, Operating cost, Growth hormone therapy, Merck, PIN, Note, Health, REACH, COVID-19 testing, Sale, Storefront, Debt-to-GDP ratio, Epstein–Barr virus, COVID-19, GeneDx, OPKO Health, Intellectual property, Modex, Immunity, Ali Baba, Research

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.

Key Points: 
  • MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
    Business highlights from the fourth quarter and subsequent weeks included the following:
    ModeX advanced its antiviral and immune-oncology product pipeline.
  • Operating loss was $16.0 million in the fourth quarter of 2023 compared with $22.0 million in the fourth quarter of 2022.
  • Total costs and expenses for the fourth quarter of 2023 were $166.4 million compared with $162.5 million in the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for the 2022 quarter.

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Other Health, Total, Forecasting, Marketing, Growth, COVID-19 testing, GAAP, COVID-19, Webcast, COVID, Patient, Lung cancer, Bank statement, Net operating loss, Research, Depreciation, Pharmaceutical industry

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023).

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023).
  • “I am exceptionally proud of the Biodesix team and our record of accomplishments in 2023,” said Scott Hutton, CEO of Biodesix.
  • I am very pleased with our significant progress on each of these goals.”
    Mr. Hutton continued, “The Biodesix team delivered 65% growth in Lung Diagnostic test volume for the full year 2023 and a sixth straight quarter of over 50% year-over-year growth, with the fourth quarter FY23 growing 54% over the fourth quarter of FY22.
  • Biodesix reported results are presented in accordance with generally accepted accounting principles in the United States (GAAP).

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health Technology, Pharmaceutical, Health, Acquisition, Investigational New Drug, Investment, COVID-19 testing, Table, Growth, NGS, GAAP, COVID-19, Carrier, Precision diagnostics, Genetics, IND, Depreciation, Bank

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2023.
  • Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.
  • Fulgent will host a conference call for the investment community today at 8:30 AM ET (5:30 AM PT) to discuss its fourth quarter and full year 2023 results.
  • Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of net income (loss) in evaluating the Company’s operating performance.

Curative Names Ellen Sexton New Chief Operating Officer

Retrieved on: 
Monday, February 26, 2024
COVID-19, Insurance, Professional Services, Health Insurance, Practice Management, Other Health, Managed Care, Health, General Health, Multimedia, Strategic planning, Growth, COVID-19 testing, Specialty, Humana, UnitedHealth Group, Prescription, Health care

Curative, a pioneering healthcare services company, is proud to announce the appointment of Ellen Sexton as Chief Operating Officer (COO).

Key Points: 
  • Curative, a pioneering healthcare services company, is proud to announce the appointment of Ellen Sexton as Chief Operating Officer (COO).
  • Ms. Sexton will be responsible for overseeing Curative’s health plan operations, ensuring seamless processes, and scaling the organization to support aggressive membership growth.
  • "I am thrilled to join Curative at such a crucial time to drive positive change in the healthcare industry," says Sexton.
  • As COO of Curative, Sexton will be responsible for overseeing the company's processes, new market development, and scaling the organization to support its aggressive growth goals.

Exact Sciences Announces Fourth Quarter 2023 Results

Retrieved on: 
Wednesday, February 21, 2024
Oncology, Medical Supplies, Health, Medical Devices, Genetics, Other Science, Science, Acquisition, Core, COVID-19 testing, Adjustment, Medicine, GAAP, COVID-19, Webcast, Patient, Net, Exact sciences, Cancer, Pharmaceutical industry

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023.

Key Points: 
  • Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023.
  • “The Exact Sciences team advanced our mission to help eradicate cancer by testing a record number of patients with Cologuard® and Oncotype DX® in the fourth quarter, leading to strong financial results,” said Kevin Conroy, Chairman and CEO of Exact Sciences.
  • The company presents EBITDA, adjusted EBITDA, non-GAAP gross margin, non-GAAP gross profit, core revenue, and free cash flow.
  • ET to discuss fourth quarter and full year 2023 results.

Mountain View Medical Laboratory Announces Rebranding to Gnosis

Retrieved on: 
Monday, February 26, 2024
Medical laboratory, Toxicology, COVID-19 testing, ABB, COVID-19, Genetics, Pathology, Health, Patient, Urine, Laboratory, Insurance, Public, Pharmaceutical industry

HEMET, Calif. , Feb. 26, 2024 /PRNewswire/ -- Mountain View Medical Laboratory, a leading and established lab backed by a decade of experience in providing a comprehensive range of testing solutions, today announced a complete rebranding to become "Gnosis."

Key Points: 
  • HEMET, Calif. , Feb. 26, 2024 /PRNewswire/ -- Mountain View Medical Laboratory, a leading and established lab backed by a decade of experience in providing a comprehensive range of testing solutions, today announced a complete rebranding to become "Gnosis."
  • For 10 years, Mountain View Medical Laboratory (MVML) has been a trusted provider of clinical lab services in Riverside County, California.
  • Gnosis is proud to offer the same great care Mountain View Medical Laboratory always has, now with expanded services and more innovative expertise.
  • Safedin "Sajo" Beqaj, Ph.D., HCLD, CC(ABB), Medical Laboratory Director - Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director.

New Approach to Urgent Care Expands to Make Healthcare More Accessible in Central New York

Retrieved on: 
Wednesday, February 7, 2024
Union, CNN, COVID-19, Vitamin, Life Itself, Child, Patient, ADHD, COVID-19 testing, Big Time Adolescence, Creativity, Workplace, COLA, Radiology, Hospital

SYRACUSE, N.Y., Feb. 7, 2024 /PRNewswire-PRWeb/ -- Drakos Clinical Dynamics, a pioneer in providing rapid, accessible healthcare innovation, is expanding its successful urgent care practice with a new location in Central New York. Drakos' mission is to provide innovative solutions that address problems impacting families, senior citizens aging-in-place, and underserved populations, all with the goal of making healthcare more accessible to everyone.

Key Points: 
  • Now, Drakos is expanding its successful urgent care practice with a new location in Central New York.
  • SYRACUSE, N.Y., Feb. 7, 2024 /PRNewswire-PRWeb/ -- Drakos Clinical Dynamics, a pioneer in providing rapid, accessible healthcare innovation, is expanding its successful urgent care practice with a new location in Central New York.
  • Drakos' original urgent care facility opened in May 2023, dedicated to pediatric urgent care.
  • The new urgent care location extends this commitment by providing accessible and inclusive healthcare for patients of all ages.

IDEX Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 6, 2024
Machine Tools, Metalworking & Metallurgy, Engineering, Technology, Manufacturing, Other Technology, Other Manufacturing, Machinery, Acceleration, EPS, Acquisition, Sale, COVID-19, COVID-19 testing, IDEX, Quarter, GAAP, Spondyloarthropathy, Finance, Pharmaceutical industry

Fourth quarter 2023 orders of $753.9 million reflected a 6% decrease compared with the prior year period (-10% organic, +3% acquisitions/divestitures and +1% foreign currency translation).

Key Points: 
  • Fourth quarter 2023 orders of $753.9 million reflected a 6% decrease compared with the prior year period (-10% organic, +3% acquisitions/divestitures and +1% foreign currency translation).
  • Fourth quarter 2023 net income attributable to IDEX decreased $21.4 million to $108.6 million, which resulted in diluted EPS attributable to IDEX of $1.43 per share, a decrease of $0.28 per share, or 16%, from the prior year period.
  • Fourth quarter 2023 net income margin of 13.7% decreased 230 basis points compared with the prior year period.
  • Fourth quarter 2023 free cash flow was $179.4 million, up 22% compared with the prior year period and constituted 129% of adjusted net income attributable to IDEX, while full year 2023 free cash flow of $626.8 million, up 28% compared with 2022, constituted 101% of adjusted net income attributable to IDEX.